Compare VanEck Australian Floating Rate ETF (FLOT) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Australian Floating Rate ETF vs TG Therapeutics Inc — how do they compare? VanEck Australian Floating Rate ETF trades at $50.94, while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: TG Therapeutics Inc is trading nearer its 52-week high, VanEck Australian Floating Rate ETF nearer its low. Which is the better fit depends on your goals.
| FLOT | TGTX | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $51.09 | $59.06 |
52-Week Low | $50.72 | $26.94 |
Market Cap | — | $7.64B |
Enterprise Value | — | $7.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLOT trades at $50.93, up 0.02% on the day, with a bearish technical signal from moving averages and oscillators neutral. Recent dividends include $0.18 paid on June 4, 2026, and $0.17 scheduled for July 7, 2026. The stock's support and resistance levels are consolidated around $51, indicating limited near-term price movement potential.
Outlook remains cautious due to bearish technical indicators and sensitivity to Federal Reserve rate decisions. Opportunities exist if rate hikes materialize, boosting yield appeal, but risks include inflation persistence and geopolitical tensions affecting Treasury yields. Investors should weigh income stability against interest rate volatility.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About VanEck Australian Floating Rate ETF
FLOT provides exposure to a diversified portfolio of Australian dollar-denominated floating rate notes. It tracks the Bloomberg AusBond Credit FRN 0+ Yr Index, focusing on high-quality, investment-grade bonds from top Australian banks and financial institutions.
Read more on FLOT →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
